Indonesia relocates residents due to Caesium-137 contamination; New York and California support Planned Parenthood against federal funding cuts; English doctors strike for job security and pay; US ...
GSK announced FDA’s approval of Blenrep in combination with bortezomib and dexamethasone (BVd) for the treatment of adults diagnosed with relapsed or refractory multiple myeloma who received a minimum ...
The FDA approved of Blenrep in combination with bortezomib and dexamethasone (BVd) for adults with relapsed or refractory multiple myeloma who have received at least two prior therapies.
16hon MSN
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of certain ...
Bay Area biopharmaceutical company Alector, Inc. is cutting dozens of jobs after the reported flop of its most recent drug trial. According to a Worker Adjustment Retraining ...
Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
FDA approves cancer drug belantamab mafodotin-blmf for relapsed multiple myeloma in combination with bortezomib and dexamethasone.
GSK's London-listed shares fell nearly 2% on Friday after the U.S. Food and Drug Administration approved only one of two ...
FDA approves GSK's Blenrep combo for relapsed multiple myeloma, showing 51% reduced death risk and tripled progression-free survival in Phase 3 trial.
GSK won approval from the U.S. Food and Drug Administration for blood-cancer drug Blenrep, paving the way for a return to the market of a medicine the company sees as a potential blockbuster.
Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback